Merrimack Financial Statements From 2010 to 2024

MACK Stock  USD 14.73  0.01  0.07%   
Merrimack Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Merrimack Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Merrimack Pharmaceuticals financial statements helps investors assess Merrimack Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Merrimack Pharmaceuticals' valuation are summarized below:
Gross Profit
-9.1 M
Market Capitalization
214.1 M
Earnings Share
(0.08)
There are currently one hundred twenty fundamental ratios for Merrimack Pharmaceuticals that can be evaluated and compared over time across peers in the industry. We recommend to check Merrimack Pharmaceuticals' last-minute fundamental drivers against the all of the trends between 2010 and 2024.

Merrimack Pharmaceuticals Total Revenue

(445,000)

Check Merrimack Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merrimack main balance sheet or income statement drivers, such as Interest Expense of 160.7 K, Total Revenue of 0.0 or Other Operating Expenses of 2.1 M, as well as many exotic indicators such as Price To Sales Ratio of 3.05, Dividend Yield of 0.31 or PTB Ratio of 10.74. Merrimack financial statements analysis is a perfect complement when working with Merrimack Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Merrimack Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Merrimack Pharmaceuticals Technical models . Check out the analysis of Merrimack Pharmaceuticals Correlation against competitors.
For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.

Merrimack Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding10.9 M14.3 M11.1 M
Slightly volatile
Total Assets18.2 M19.2 M86.6 M
Slightly volatile
Short and Long Term Debt Total16.2 M17.1 M58 M
Pretty Stable
Other Current Liabilities348.6 K367 K25.7 M
Slightly volatile
Total Current Liabilities418.9 K441 K36.6 M
Slightly volatile
Property Plant And Equipment Net2.5 M2.6 M7.2 M
Slightly volatile
Current Deferred Revenue25.4 M41.7 M30.8 M
Slightly volatile
Accounts Payable70.3 K74 K3.3 M
Slightly volatile
Cash5.7 MM42.9 M
Slightly volatile
Non Current Assets Total3.8 KK13.8 M
Slightly volatile
Non Currrent Assets Other3.8 KK994.9 K
Pretty Stable
Cash And Short Term Investments17.9 M18.9 M64.7 M
Slightly volatile
Common Stock Total Equity1.8 M1.2 M2.3 M
Slightly volatile
Liabilities And Stockholders Equity18.2 M19.2 M86.6 M
Slightly volatile
Other Current Assets293.6 K309 K3.3 M
Slightly volatile
Other Stockholder Equity507.8 M566.2 M492 M
Slightly volatile
Total Liabilities418.9 K441 K140.6 M
Slightly volatile
Property Plant And Equipment Gross2.5 M2.6 M7.2 M
Slightly volatile
Total Current Assets18.2 M19.2 M72.8 M
Slightly volatile
Short Term Debt14.6 M15.3 M29.3 M
Very volatile
Common Stock1.7 M1.3 M2.3 M
Slightly volatile
Other Liabilities47.9 K50.4 K28.9 M
Slightly volatile
Property Plant Equipment2.5 M2.6 M7.2 M
Slightly volatile
Long Term Debt Total16.2 M17.1 M71.4 M
Slightly volatile
Capital Surpluse625.9 M650.4 M563.3 M
Slightly volatile
Inventory111.4 K117.3 K1.3 M
Very volatile
Deferred Long Term LiabilitiesM1.1 M29.3 M
Slightly volatile
Short and Long Term Debt218 M249.4 M189.5 M
Slightly volatile
Net Invested Capital29.2 M18.7 M63.9 M
Slightly volatile
Long Term Investments7.2 M6.7 MM
Slightly volatile
Net Working Capital25.2 M18.7 M51.5 M
Slightly volatile
Capital Stock1.5 M1.3 M1.3 M
Slightly volatile

Merrimack Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense160.7 K169.2 KM
Pretty Stable
Other Operating Expenses2.1 M2.2 M87.6 M
Slightly volatile
Cost Of Revenue380.5 K400.5 K47.1 M
Slightly volatile
Total Operating Expenses2.1 M2.2 M77.9 M
Slightly volatile
Selling General Administrative2.1 M2.2 M19.9 M
Slightly volatile
Selling And Marketing Expenses4.5 M5.1 M5.5 M
Slightly volatile
Discontinued Operations4.3 M4.5 M41.2 M
Very volatile
Non Recurring7.4 M10.9 M7.8 M
Slightly volatile
Interest Income687.8 K724 K7.8 M
Slightly volatile
Extraordinary Items4.3 M4.5 M39.8 M
Very volatile

Merrimack Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation152 K160 K6.1 M
Slightly volatile
Begin Period Cash Flow37.8 M19.4 M45.9 M
Pretty Stable
End Period Cash Flow5.7 MM43 M
Slightly volatile
Sale Purchase Of Stock5.6 M5.9 M10.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.053.216.4207
Slightly volatile
Dividend Yield0.310.570.5352
Slightly volatile
Days Sales Outstanding88.5150.8265.3894
Slightly volatile
Stock Based Compensation To Revenue0.110.120.2239
Slightly volatile
Inventory Turnover0.450.430.2852
Slightly volatile
Days Of Inventory On Hand84088412.3 K
Slightly volatile
Payables Turnover2.592.725.1571
Slightly volatile
Sales General And Administrative To Revenue0.260.270.2991
Pretty Stable
Research And Ddevelopement To Revenue1.321.01.2635
Very volatile
Cash Per Share1.251.329.1831
Slightly volatile
Days Payables Outstanding13213910.8 K
Slightly volatile
Intangibles To Total Assets0.120.110.0978
Pretty Stable
Current Ratio45.6843.501113.3595
Slightly volatile
Receivables Turnover7.787.439.1376
Very volatile
Graham Number1.481.560955.3798
Slightly volatile
Revenue Per Share6.4410.368.8255
Slightly volatile
Debt To Assets0.140.150.6934
Slightly volatile
Days Of Payables Outstanding13213910.8 K
Slightly volatile
Ebt Per Ebit0.510.53721.0154
Slightly volatile
Quick Ratio44.9442.800512.8022
Slightly volatile
Cash Ratio14.2613.58058.2333
Slightly volatile
Days Of Inventory Outstanding84088412.3 K
Slightly volatile
Days Of Sales Outstanding88.5150.8265.3894
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.840.91.0013
Pretty Stable
Fixed Asset Turnover8.658.247.2865
Slightly volatile
Debt Ratio0.140.150.6934
Slightly volatile
Price Sales Ratio3.053.216.4207
Slightly volatile
Asset Turnover1.671.591.1791
Slightly volatile
Operating Cycle6957318.4 K
Slightly volatile

Merrimack Fundamental Market Drivers

Cash And Short Term Investments18.9 M

Merrimack Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Merrimack Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Merrimack Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Merrimack Pharmaceuticals investors use historical funamental indicators, such as Merrimack Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Merrimack Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Merrimack Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merrimack Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Merrimack Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Merrimack Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue41.7 M25.4 M
Total Revenue-445 K0.0
Cost Of Revenue400.5 K380.5 K
Stock Based Compensation To Revenue 0.12  0.11 
Sales General And Administrative To Revenue 0.27  0.26 
Research And Ddevelopement To Revenue 1.00  1.32 
Capex To Revenue(0.02)(0.02)
Revenue Per Share 10.36  6.44 
Ebit Per Revenue(0.69)(0.72)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merrimack Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merrimack Pharmaceuticals' short interest history, or implied volatility extrapolated from Merrimack Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merrimack Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merrimack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merrimack Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Merrimack Pharmaceuticals Stock:
Check out the analysis of Merrimack Pharmaceuticals Correlation against competitors.
For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.
Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Merrimack Stock analysis

When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.08)
Return On Assets
(0.07)
Return On Equity
(0.06)
The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.